BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Gavin Clark-Gartner does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 PRQRProQR Therapeutics BV | Buy | $5.00 | Apr 2025 | −10.7% | Miss |
 FHTXFoghorn Therapeutics Inc | Buy | $20.00 | Aug 2024 | −26.2% | Miss |
 CABACabaletta Bio Inc | Buy | $15.00 | Aug 2024 | −59.1% | Miss |
 MIRMMirum Pharmaceuticals Inc | Buy | $62.00 | Oct 2023 | +22.4% | Miss |
 ARGXargenx NV ADR | Buy | $436.00 | Jul 2023 | −22.2% | Hit |
 CCCCC4 Therapeutics Inc | Buy | $10.00 | May 2023 | +34.6% | Hit |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.